Finance

Beta
Lists
Equity sectors
Symbols
Symbols
Price
Change
% Change
Trend
Prev Close
Open
High
Low
Volume
Mkt Cap
SIXB
Materials
SIXB
Materials
SIXB
-0.27%
1,101.09
-3.01
-0.27%
1,104.101,103.921,108.751,097.16
SIXC
Communications
SIXC
Communications
SIXC
+0.46%
606.91
+2.75
+0.46%
604.16604.16610.19604.12
SIXE
Energy
SIXE
Energy
SIXE
+0.05%
1,198.37
+0.56
+0.05%
1,197.811,200.581,213.071,192.02
SIXI
Industrials
SIXI
Industrials
SIXI
-0.10%
1,738.73
-1.68
-0.10%
1,740.411,739.551,750.271,730.60
SIXM
Financials
SIXM
Financials
SIXM
+0.56%
637.97
+3.53
+0.56%
634.44633.13639.67633.01
SIXR
Staples
SIXR
Staples
SIXR
-0.87%
833.59
-7.31
-0.87%
840.90839.53841.73833.03
SIXRE
Real estate
SIXRE
Real estate
SIXRE
-0.37%
214.33
-0.80
-0.37%
215.13215.13215.85213.89
SIXT
Technology
SIXT
Technology
SIXT
-0.11%
3,225.10
-3.61
-0.11%
3,228.713,225.623,227.743,198.95
SIXU
Utilities
SIXU
Utilities
SIXU
+0.20%
937.71
+1.84
+0.20%
935.87938.37942.00936.95
SIXV
Health care
SIXV
Health care
SIXV
-0.37%
1,451.76
-5.36
-0.37%
1,457.121,452.741,466.881,449.55
SIXY
Discretionary
SIXY
Discretionary
SIXY
-0.53%
2,387.04
-12.80
-0.53%
2,399.842,389.712,394.612,371.22
CTSO:NASDAQ
Cytosorbents Corp
$0.62
-2.10%
(-0.013) 1D
Apr 27, 2:34:53 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for CTSO...
Open
$0.63
High
$0.65
Low
$0.61
Mkt. cap
38.45M
Avg. vol.
99.75K
Volume
35.78K
52-wk high
$1.39
52-wk low
$0.50
EPS
-$0.13
Beta
1.47
Shares outstanding
62.80M
No. of employees
129
News stories
From sources across the web
Profile
CytoSorbents Corporation is a publicly traded company located in Princeton, New Jersey. CytoSorbents sells a cytokine adsorbing column — a blood purification technology based on porous polymer beads that act like sponges in an attempt to remove harmful inflammatory mediators like Cytokines, Bilirubin, Myoglobin from the blood. The use of hemoperfusion columns is generally limited to patients who are critically ill in high-resource counties, and they require a patient to be connected to a hemofiltration system such as Dialysis, Hemofiltration Cardiopulmonary bypass or ECMO. Other blood purification devices are using different technologies with different performance parameters. This is including polymyxin B hemoperfusion columns, which failed to show significance in a clinical trial for sepsis. The CytoSorb technology has actually the largest body of clinical data confirming safety and efficacy. Clinicaltrials.gov is giving an overview over running research projects. CytoSorbents was awarded a $3.8 million contract by Defense Advanced Research Projects Agency for its “Dialysis-Like Therapeutics” program to treat sepsis by removing cytokines and pathogen-derived toxins. Wikipedia
About Cytosorbents Corp
CEO-
Employees129
Founded1997
Headquarters-
SectorMedical device
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Revenue
8.73M
9.62M
9.48M
9.23M
Cost of goods sold
2.52M
2.80M
2.82M
2.43M
Cost of revenue
2.52M
2.80M
2.82M
2.43M
Research and development expenses
1.66M
1.26M
918.00K
1.24M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
8.43M
9.17M
8.41M
9.61M
Operating expense
10.09M
10.43M
9.33M
10.86M
Total operating expenses
12.61M
13.23M
12.15M
13.28M
Operating income
-3.89M
-3.62M
-2.66M
-4.05M
Other non operating income
-
-
-
-
EBT including unusual items
-1.48M
1.95M
-3.57M
-5.50M
EBT excluding unusual items
-1.48M
1.95M
-3.37M
-4.60M
Income tax expense
-
-
-401.00K
-
Effective tax rate
-
-
11.23%
-
Other operating expenses
-
-
-
-
Net income
-1.48M
1.95M
-3.17M
-5.50M
Net profit margin
-16.94%
20.25%
-33.42%
-59.53%
Earnings per share
-
-
-
-
Interest and investment income
-
-
-
-
Interest expense
-605.13K
-616.00K
-645.00K
-746.00K
Net interest expenses
-605.13K
-616.00K
-645.00K
-746.00K
Depreciation and amortization charges
-
-
-
-
EBITDA
-3.52M
-3.21M
-2.30M
-3.69M
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more

Research

My tasks
You haven't created a task yet
Your tasks will appear here. Schedule tasks and put Google Finance to work while you're away.
Templates
Watchlist briefing
A daily pre-market analysis of your watchlist
Upcoming Earnings
Upcoming earnings reports in the week
Abnormal Volatility & Volume
Volatility and volume early warning today
AI content may include mistakes. Learn more